Semaglutide, optimal therapy for type 2 diabetes with few side effects: Study
Written By : Medha Baranwal
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2022-06-02 05:15 GMT | Update On 2022-06-02 07:09 GMT
Advertisement
Egypt: Tirzepatide, oral, and subcutaneous (SC) semaglutide have a favorable efficacy for type 2 diabetes treatment, according to results from a meta-analysis. The adverse events were found to be comparable to placebo; however, a high rate of gastrointestinal adverse events was seen in tirzepatide, oral, and SC semaglutide groups.
The study, published in Diabetes & Metabolic Syndrome: Clinical Research & Reviews, showed that semaglutide at 1 mg SC weekly dose and 14 mg oral dose were the favorable doses. Also, semaglutide showed more reduction in fasting blood glucose, HbA1c, and body weight versus other anti-diabetic medications.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.